A novel model of the continual reassessment method in Phase I trial

Weijia Zhang, Wanni Lei*, Xiaojun Zhu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Downloads (Pure)


For the model-based designs, the continual reassessment method (CRM) is widely used to identify the maximum tolerated dose (MTD) in phase I clinical trials. To improve the performance of classic CRM models, we propose a new CRM and its dose-toxicity probability function based on the Cox model whatever the treatment response is immediately observed or delayed. In the process of dose-finding trial, we can use our model in situations when either the response is delayed or not and can derive the likelihood function and posterior mean toxicity probabilities to find the MTD. Simulation is carried out to evaluate the performance of the proposed model with the classic CRM models. We also evaluate the operating characteristics of the proposed model by the Efficiency, Accuracy, Reliability, and Safety (EARS) criteria.

Original languageEnglish
Article number5047
JournalScientific Reports
Issue number1
Publication statusE-pub ahead of print - Mar 2023


Dive into the research topics of 'A novel model of the continual reassessment method in Phase I trial'. Together they form a unique fingerprint.

Cite this